Keywords
Clinical endpointArgument (complex analysis)Multiplicity (mathematics)Clinical trialPsychologyMedicineEconometricsMathematicsInternal medicine
Affiliated Institutions
Related Publications
Investigating patient exclusion bias in meta-analysis
Trials, systematic reviews, and meta-analyses may be prone to bias associated with post-randomization exclusion of patients. Wherever possible, the level of such exclusions shou...
Surrogate endpoints in clinical trials: Definition and operational criteria
Abstract I discuss the idea of using surrogate endpoints in the context of clinical trials to compare two or more treatments or interventions in respect to some ‘true’ endpoint,...
AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both
The number of published systematic reviews of studies of healthcare interventions has increased rapidly and these are used extensively for clinical and policy decisions. Systema...
Meta-analysis for the evaluation of potential surrogate markers
We describe a meta-analysis approach for the evaluation of a potential surrogate marker. Surrogate markers are useful in helping to identify therapeutic mechanisms of action and...
Evaluating surrogate markers.
We discuss approaches for efficiently evaluating potential surrogate markers; in particular, we focus on case-cohort designs in which marker evaluation is undertaken only for a ...
Publication Info
- Year
- 2005
- Type
- article
- Volume
- 365
- Issue
- 9470
- Pages
- 1591-1595
- Citations
- 367
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
367
OpenAlex
Cite This
Kenneth F. Schulz,
David A. Grimes
(2005).
Multiplicity in randomised trials I: endpoints and treatments.
The Lancet
, 365
(9470)
, 1591-1595.
https://doi.org/10.1016/s0140-6736(05)66461-6
Identifiers
- DOI
- 10.1016/s0140-6736(05)66461-6